CING vs. OGEN, NEXI, LIPO, CPHI, PTPI, ALZN, XCUR, ARTL, DRUG, and ENSC
Should you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Oragenics (OGEN), NexImmune (NEXI), Lipella Pharmaceuticals (LIPO), China Pharma (CPHI), Petros Pharmaceuticals (PTPI), Alzamend Neuro (ALZN), Exicure (XCUR), Artelo Biosciences (ARTL), Bright Minds Biosciences (DRUG), and Ensysce Biosciences (ENSC). These companies are all part of the "pharmaceutical preparations" industry.
Oragenics (NYSE:OGEN) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
Cingulate received 6 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 66.67% of users gave Cingulate an outperform vote while only 0.00% of users gave Oragenics an outperform vote.
18.7% of Oragenics shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 24.6% of Oragenics shares are held by insiders. Comparatively, 38.4% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Oragenics' return on equity of 0.00% beat Cingulate's return on equity.
Cingulate has a consensus target price of $8.00, suggesting a potential upside of 800.90%. Given Oragenics' higher probable upside, analysts plainly believe Cingulate is more favorable than Oragenics.
In the previous week, Cingulate had 4 more articles in the media than Oragenics. MarketBeat recorded 6 mentions for Cingulate and 2 mentions for Oragenics. Oragenics' average media sentiment score of -0.04 beat Cingulate's score of -0.24 indicating that Cingulate is being referred to more favorably in the news media.
Oragenics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.87, suggesting that its stock price is 187% less volatile than the S&P 500.
Oragenics has higher revenue and earnings than Cingulate. Oragenics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.
Summary
Cingulate beats Oragenics on 10 of the 15 factors compared between the two stocks.
Get Cingulate News Delivered to You Automatically
Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cingulate Competitors List
Related Companies and Tools
